Gerard Silvestri to Cost-Benefit Analysis
This is a "connection" page, showing publications Gerard Silvestri has written about Cost-Benefit Analysis.
Connection Strength
0.511
-
Evaluating Lung Cancer Screening Uptake, Outcomes, and Costs in the United States: Challenges With Existing Data and Recommendations for Improvement. J Natl Cancer Inst. 2019 04 01; 111(4):342-349.
Score: 0.140
-
New testing for lung cancer screening. Oncology (Williston Park). 2012 Feb; 26(2):176-82.
Score: 0.085
-
Screening for lung cancer. AJR Am J Roentgenol. 2008 Mar; 190(3):755-61.
Score: 0.065
-
The Cost-Effectiveness of Nicotine Replacement Therapy Sampling in Primary Care: a Markov Cohort Simulation Model. J Gen Intern Med. 2022 11; 37(14):3684-3691.
Score: 0.043
-
Treatment strategies for insulin-dependent diabetics with ESRD: a cost-effectiveness decision analysis model. Am J Kidney Dis. 1998 May; 31(5):794-802.
Score: 0.033
-
Cost-effectiveness of head CT in patients with lung cancer without clinical evidence of metastases. Chest. 1995 Nov; 108(5):1264-71.
Score: 0.028
-
Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts. PLoS Med. 2014 Dec; 11(12):e1001764.
Score: 0.026
-
Cost-effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med. 2014 Nov 06; 371(19):1793-802.
Score: 0.026
-
Quality-of-life improvement and cost-effectiveness of interventional pulmonary procedures. Clin Chest Med. 2013 Sep; 34(3):593-603.
Score: 0.023
-
Tissue verification of stage I sarcoidosis: the question is if, not how. Chest. 2008 Jun; 133(6):1529-1530.
Score: 0.017
-
Screening for lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007 Sep; 132(3 Suppl):69S-77S.
Score: 0.016
-
Cost-efficacy of endoscopic ultrasonography with fine-needle aspiration vs. mediastinotomy in patients with lung cancer and suspected mediastinal adenopathy. Endoscopy. 1999 Nov; 31(9):707-11.
Score: 0.009